Tuberculosis (TB) infects two-thirds of the world population. Despite forty years of drugs that can cure TB, it continues to increase at a significant rate. This is primarily due to the growing HIV epidemic, which facilitates the conversion of latent TB to the active disease, and the long and complicated chemotherapy required to cure TB, which results in widespread non-compliance. Reducing non-compliance, by reducing the duration of chemotherapy will have a great impact on TB control. In an infection, a fraction of Mycobacterium tuberculosis exist in a dormant, non-replicating state that persists in the face of cidal drugs and/or innate and adaptive killing mechanisms. Therefore, the development of new drugs that either kill these persisting organisms, inhibit bacilli from entering the persistent phase, or convert the persistent bacilli into actively growing cells susceptible to our current drugs will have a positive effect. We are taking a multi-discipline approach that will identify and characterize new drug targets that are essential for persistent M. tuberculosis. Targets will be exposed to a battery of analyses including microarray experiments, bioinformatics, and genetic techniques to prioritize potential drug targets from Mtb for structural analysis. Top targets will be identified and prioritized by our scientific advisory panel, and allocated to one of the laboratories the Program Project or a TBSGC laboratory based on their level of interest, expertise and available resources. Our Core structural genomics pipeline will work with the individual laboratories to produce diffraction quality crystals of targeted proteins, and structural analyses will be completed by the individual laboratories. We also have in the Program Project the capabilities for functional analysis, and virtual ligand screening to identify novel inhibitors for target validation. Our overarching goals are to increase the knowledge of Mtb pathogenesis using the TB research community to drive structural genomics, particularly related to persistence, develop a central repository forTB research, and discover chemical inhibitors of drug targets for future development of lead compounds.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-AR-M (S2))
Program Officer
Lacourciere, Karen A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Texas Agrilife Research
Schools of Earth Sciences/Natur
College Station
United States
Zip Code
Wagner, Jonathan M; Chan, Sum; Evans, Timothy J et al. (2016) Structures of EccB1 and EccD1 from the core complex of the mycobacterial ESX-1 type VII secretion system. BMC Struct Biol 16:5
Prigozhin, Daniil M; Papavinasasundaram, Kadamba G; Baer, Christina E et al. (2016) Structural and Genetic Analyses of the Mycobacterium tuberculosis Protein Kinase B Sensor Domain Identify a Potential Ligand-binding Site. J Biol Chem 291:22961-22969
DeJesus, Michael A; Zhang, Yanjia J; Sassetti, Christopher M et al. (2013) Bayesian analysis of gene essentiality based on sequencing of transposon insertion libraries. Bioinformatics 29:695-703
Liu, Zhen; Ioerger, Thomas R; Wang, Feng et al. (2013) Structures of Mycobacterium tuberculosis FadD10 protein reveal a new type of adenylate-forming enzyme. J Biol Chem 288:18473-83
Ioerger, Thomas R; O'Malley, Theresa; Liao, Reiling et al. (2013) Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS One 8:e75245
Miallau, Linda; Jain, Paras; Arbing, Mark A et al. (2013) Comparative proteomics identifies the cell-associated lethality of M. tuberculosis RelBE-like toxin-antitoxin complexes. Structure 21:627-37
Tretter, Elsa M; Berger, James M (2012) Mechanisms for defining supercoiling set point of DNA gyrase orthologs: II. The shape of the GyrA subunit C-terminal domain (CTD) is not a sole determinant for controlling supercoiling efficiency. J Biol Chem 287:18645-54
Min, Andrew B; Miallau, Linda; Sawaya, Michael R et al. (2012) The crystal structure of the Rv0301-Rv0300 VapBC-3 toxin-antitoxin complex from M. tuberculosis reveals a Mgýýýýý ion in the active site and a putative RNA-binding site. Protein Sci 21:1754-67
Tretter, Elsa M; Berger, James M (2012) Mechanisms for defining supercoiling set point of DNA gyrase orthologs: I. A nonconserved acidic C-terminal tail modulates Escherichia coli gyrase activity. J Biol Chem 287:18636-44
Chim, Nicholas; Owens, Cedric P; Contreras, Heidi et al. (2012) Advances In Mycobacterium Tuberculosis Therapeutics Discovery Utlizing Structural Biology. Infect Disord Drug Targets :

Showing the most recent 10 out of 50 publications